SensDx is working on the technology of ultra-sensitive micorsensors, modified with biological molecules. The molecules on the electrode surface are selected by biotechnological methods. It allows you to identify unambiguously which bacteria or virus is the cause of infection or to determine the oncological marker, DNA or RNA.
Currently, works in the field of cardiology, oncology, urology and veterinary medicine are being carried out.
Multi SensDx - test for identification of upper respiratory tract infections causes
Multisensor is a rapid diagnostic test to identify the etiology of an upper respiratory tract infection that identifies more than one pathogen in a single sample. Proper diagnosis of the causes of the infection will allow for effective and precise therapy, which will reduce the unnecessary use of antibiotics in cases where the infection is viral.
SensDx has received positive grant recommendation from Agency of Medical Research for research and mass production implementation of SARS-CoV-2 diagnostics.
SensDx and the team of prof. Krzysztof Pyrc from Małopolska Centre of Biotechnology of the Jagiellonian University undertook joint activities to develop an ultrafast diagnostic test for SARS-CoV-2 virus (COVID-19).
We are growing! Our digital diagnostic platforms for influenza virus detection are now available in over 100 medical facilities across Poland!
Our vision is to revolutionize medical diagnosis worldwide by providing effective, rapid and easy-to-use tests to detect pathogens causing specific diseases.
Our mission is to prevent the spreading of bacteria and viruses by detecting pathogens at an early stage of development.
The innovative solution combines a simple tool based on a fast, ultra-sensitive diagnostic test with a mobile application for easy result interpretation.
The test tools are placed inside specially-designed devices called Mobi (for individual patients) or Pro (for medical professionals)
SensDX comprises of an interdisciplinary team of experts specialising in biotechnological, chemical, electrochemical and electronic sciences, IT, production automation and business, including IP protection, technology commercialisation, sales and marketing. We work in line with modern management methods, high quality standards and safety regulations.
The dynamic growth of SensDx has been facilitated by funds obtained through a wide range of subsidies. While evaluating the SensDx applications, experts appreciated not only the technology, which will have a wide range of applications in telemedicine and diagnostics, but also the innovative functionality, huge commercialisation potential and business model, implemented consistently by SensDx.Learn more
District Court for the Capital City of Warsaw in Warsaw
XIII Commercial Department of the National Court Register
Share capital: 100 000 zł (paid in full)
ul. Postępu 14B, 02-676 Warszawa
ul. Kładki 24, 80-822 Gdańsk
ul. Bierutowska 57-59, 51-317 Wrocław
(Wrocławski Park Biznesu 3)
ul. Nałęczowska 14, 20-701 Lublin
Poland, Czech Republic, Slovakia, Hungary